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Abstract
Background: Point-of-care (POC) tests are an important strategy to address the epidemic of sexually transmitted
infections (STIs). The leucocyte esterase test (LET) can be used as a POC test for chlamydia. The aim of this study was to
determine the diagnostic accuracy of the LET to detect urogenital chlamydia among men at STI clinics in Paramaribo,
Suriname and Amsterdam, the Netherlands.
Methods: Recruitment of patients took place in 2008–2010 in Suriname and in 2009–2010 in the Netherlands. Urine of
patients was examined with the LET. The reference test was a nucleic acid amplification test (NAAT).
Results: We included 412 patients in Suriname and 645 in the Netherlands. Prevalence of chlamydia in Suriname and
the Netherlands was respectively 22.8 and 13.6 %. The sensitivity of the LET was 92.6 % (95 % CI = 85.3–97.0) and 77.
3 % (95 % CI = 67.1–85.5) respectively, the specificity was 38.1 % (95 % CI = 32.7–43.6 %) and 58.1 % (95 % CI = 53.9–62.3)
respectively. The positive predictive value was 30.6 % (95 % CI = 27.3–36.4) and 22.6 % (95 % CI = 18.0–27.7) respectively
and the negative predictive value was 94.5 % (95 % CI = 89.1–97.8) and 94.2 % (95 % CI = 91.1–96.4) respectively. The
kappa was respectively 0.179 and 0.176.
Conclusions: To diagnose urogenital chlamydia in men the LET performs poorly. It has a high negative but low positive
predictive value. If the LET result is negative, chlamydia is accurately excluded, yet a positive result has a low predictive
value. Whether the advantages of direct management based on LET outweigh the disadvantages of overtreatment is a
subject for further studies.
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Background
Chlamydia trachomatis (Ct) is the most common cause
of nongonoccal urethritis in men [1]. In resource-limited
settings management of male urethritis is generally
based on a syndromic approach: when a patient has typ-
ical symptoms like urethral discharge, penile itching or
dysuria, immediate treatment with antibiotics is given.
Yet, with a syndromic approach, a significant proportion
of men infected with Ct are missed, as the majority of
men does not have symptoms [2]. The proportion of
cases that are asymptomatic varies by population and
ranges from 40 to 96 % [3–5]. Moreover, a syndromic
approach also can lead to overtreatment, antibiotic over-
consumption, induction of side effects and antimicrobial
resistance of infections like Neisseria gonorrhoeae (Ng).
Also, effective contact tracing and treatment is challen-
ging based on a presumptive diagnosis only.
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Point of care (POC) management can partly overcome
the disadvantages of syndromic management. POC test-
ing is defined as medical testing at or near the site of
patient care [6]. Ideally a POC test should meet the AS-
SURED criteria of the World Health Organization; Af-
fordable, Sensitive, Specific, User-friendly, Rapid and
Robust, Equipment-free, Deliverable to those who need
them [7]. Recently, several companies have developed
commercial POC tests based on bacterial antigens that
provide rapid results for the detection of Ct, but the sen-
sitivity of these tests is low (17–65 %) and this precludes
more widespread use in clinical settings [6, 8–10]. The
Cepheid GeneXpert Ct/Ng assay is a rapid (<2 h to re-
sults) nucleic acid amplification test (NAAT) assay that
can be performed in on-site laboratories, but the high
costs are an obstacle for implementation in low-and
middle-income countries. Moreover it is questionable if
patients are willing to wait 2 h for their test result [11].
As long as no other promising POC test is available, sexu-
ally transmitted infections (STI) clinics are dependent on
convential techniques like light microscopy and dipstick
urinalysis with the leucocyte esterase test (LET).
Light microscopy is used in the POC management of
various STIs [1]. However, light microscopy requires a
laboratory infrastructure that is often lacking in resource-
limited settings. In these settings the LET might be an
alternative for light microscopy, because it is cheap, easy
to perform and does not require a laboratory [12, 13].
LET is available as dipstick assay and is used to detect a
urinary inflammatory reaction through the presence of an
esterase enzyme produced by polymorph nuclear leuco-
cytes (PMNL) in the urine, possibly associated with either
a urinary tract infection or STI in males [14].
Suriname is a middle-income country in South America
with most of the population concentrated in the coastal
region, and the remainder in sparsely populated, predom-
inantly remote areas. For these settings, an equipment-
free POC test could be of great benefit. The Netherlands
is a high-income country in Europe, but also there an
equipment-free POC test may be useful in certain primary
health care settings like general practitioners clinics.
Previous studies that investigated the performance of
the LET to detect urogenital Ct in males have reported
sensitivities and specificities ranging from 46 to 100 %
and 60 to 96 % respectively [15–19]. The variety of out-
comes can be explained by a difference in settings, pa-
tient groups, experimental test thresholds and reference
tests. In most of the studies obsolete reference tests like
ligase chain reaction (LCR) were used and/or investi-
gated the LET in either symptomatic or asymptomatic
patients in one setting [16, 20–28].
The aim of our study was to evaluate the diagnostic per-
formance of the LET as a POC test for urogenital Ct com-
pared to NAAT in male patients irrespective of symptoms
attending STI outpatient clinics in two different settings;
an outpatient clinic in a middle-income country,
Suriname, and in a high-income country, the Netherlands.
Methods
Study design, selection of patients
Participants were recruited at:
1. The Dermatological Service in Paramaribo, an
integrated outpatient clinic that offers free-of-charge
examination and treatment of STIs and infectious skin
diseases such as leprosy and leishmaniasis. Recruit-
ment took place between March 2008 and July 2010.
2. The STI Outpatient Clinic of the Public Health
Service of Amsterdam, which is a low threshold
clinic serving over 40,000 patients annually. Patients
were prioritized based on a short questionnaire to
estimate the risk of having an STI, as described
before [29]. The following categories were regarded
as high risk: age <25 years, men who have sex with
men, born in an STI and HIV endemic country,
receiving money/goods for sex, paying for sex, ≥3
partners in the previous 6 months, reporting a sexual
partner with a partner born in an STI and HIV
endemic country, being notified by a sex partner or
having STI related symptoms. Patients regarded as
high-risk were eligible to participate; recruitment took
place between November 2009 and May 2010.
In both countries demographic characteristics and data
regarding symptoms were obtained using a question-
naire. Patients were regarded as symptomatic when ei-
ther dysuria, urethral discharge or scrotal pain was
reported in the questionnaire.
Leucocyte esterase test (LET)
The LET (Combur2 Test LN, Roche Diagnostics, GmbH,
Mannheim, Germany) is a non-specific rapid dipstick assay
used to detect the presence of an esterase enzyme pro-
duced by PMNL's in urine. The presence of PMNL's in
urine indicates an inflammatory response, possibly caused
by an infection. In Suriname and the Netherlands patients
provided urine samples that were immediately brought to
the on-site laboratory by nurses. A laboratory technician
performed the LET within two hours of sample collection
and placed the dipstick in a urine sample according to
the manufacturer’s instructions. The results were read
after 2 and 5 min. Using a reference color table, the
dipstick differentiated between negative, 1+ (ca. 10–25
PMNL/μl), 2+ (ca. 75 PMNL/μl), 3+ (ca. 500 PMNL/
μl). The LET was regarded positive when the dipstick
colored ≥ 1+. Patients with a failed or missing LET were
excluded from the analyses.
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Reference tests
The Aptima Ct assay (Hologic Gen-Probe, USA) was
used as the reference NAAT to detect urogenital Ct both
in the Netherlands and Suriname. Reference testing was
performed on the same urine sample that was used for
the LET. In the Netherlands the samples were tested
the same week at the Public Health Laboratory in
Amsterdam. In Suriname, the samples were collected
according to the manufacturer’s (Hologic) instruc-
tions, stored in a fridge (at temperature between 2°
and 7 °C) and packed according to international air
transport association (IATA) rules for transport by
plane to the Public Health Laboratory in Amsterdam
for NAAT testing. According to the manufacturer’s
instructions the samples had to be analysed within
30 days after collection. In our study 349 of the 412
samples (84.7 %) were analysed within 30 days and 63
samples (15.3 %) were tested between 31 and 48 days
(median time: 35 days (IQR 33–36 days)). More de-
tails about the data collection were previously de-
scribed [8, 30].
Diagnostic performance and statistical analysis
The diagnostic performance of the LET was investigated by
calculating the sensitivity, specificity, positive predictive
value (PPV), negative predictive value (NPV), the percent-
age agreement and kappa. A kappa value >0.61 was consid-
ered as good test agreement, κ = 0.41–0.60 as fair
agreement, κ = 0.21–0.40 as slight agreement, κ = 0.01–0.20
as poor agreement, and κ ≤ 0.00 as no agreement) [31].
As prescribed by the manufacturer the LET was read
2 min after it was placed in urine (from here onwards
described as “LET 2 m”). We also read the result of the
LET 5 min after it was placed in urine (from now on de-
scribed as “LET 5 m”) to evaluate the influence of timing
on the diagnostic performance.
We compared the diagnostic performance of the LET
2 m between symptomatic and asymptomatic patients and
conducted a subgroup analysis for individuals <25 years.
Characteristics of the study populations were compared
using the Pearson’s chi-square test. When the expected
cell-count was <5 the Fisher’s exact test was used. We
considered a p-value <0.05 as statistically significant. Ana-
lyses were performed with SPSS package version 21 (SPSS
Inc., Chicago, Illinois, USA) and STATA software V11.2




In total 415 patients provided samples for the study, of
which three patients had an invalid LET result and were
excluded. From the remaining 412 patients 279 (67.7 %)
of the patients were symptomatic and 133 (32.3 %) were
asymptomatic. The median age was 28 years (interquartile
range (IQR) 24.0–37.0). Ct prevalence was 22.8 % (95 %
CI 19.0–27.1) (Table 1).
The Netherlands
In total 647 patients provided samples for the study of
which two patients had an invalid LET result and were
excluded. Data regarding symptoms were missing for nine
patients. Among the remaining 636 patients 257 (40.4 %)
of the patients were symptomatic and 379 (59.6 %) were
asymptomatic. The median age was 34 years (IQR 26.5–
43.0). Ct prevalence was 13.6 % (95 % CI 11.2–16.5).
Table 1 Characteristics of male patients included at the
Dermatological Service Paramaribo, Suriname, 2008–2010 and the






Demographic characteristics n (%) n (%)
Median age (years) (IQR) 28.0 (24.0–37.0) 34.0 (26.5–43.0) <0.001
Age (years) <0.001
< 25 109 (26.5) 110 (17.1)
25–29 115 (27.9) 123 (19.1)
30–34 59 (14.3) 108 (16.7)
≥ 35 129 (31.3) 304 (47.1)
Symptoms* <0.001
No 133 (32.3) 379 (59.6)
Yes 279 (67.7) 257 (40.4)
HIV status** <0.001
Negative 392 (95.1) 519 (80.5)
Positive 2 (0.49) 113 (17.5)
Unknown 18 (4.4) 13 (2.0)
Sexual preference* <0.001
Heterosexual men 402 (98.3) 282 (43.7)
Men who have sex
with men
7 (1.7) 363 (56.3)
Ct prevalence
Total population 94 (22.8) 88 (13.6) <0.001
< 25 years 29 (26.6) 21 (19.1) 0.185
Symptomatic patients* 77 (27.6) 53 (20.6) 0.060
Asymptomatic patients* 17 (12.8) 34 (9.0) 0.207
Abbreviations: STI sexual transmitted infections; IQR interquartile range; Ct
Chlamydia trachomatis
*Numbers do not add up to column total due to missing data; data on symptoms
were missing for 9 patients in the Netherlands and data on sexual preference
were missing for 3 patients in Suriname. Percentages were calculated based on
those with non-missing data and thus add up to 100 %
**In the Netherlands a positive HIV status was based on a positive HIV test in
the past or on the date of inclusion (noted in the patient records); a negative
HIV status was based on a negative HIV test result on the date of inclusion.
The HIV status was unknown when a HIV test was lacking on the date of
inclusion. In Suriname the HIV status was self-reported at the date of inclusion
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Ct prevalence and symptomatology in Suriname and the
Netherlands
In Suriname significantly more patients reported symp-
toms compared with the Netherlands; 67.7 % (279/412)
versus 40.4 % (257/636) (p < 0.001). Also a significantly
higher prevalence of Ct was found in Suriname than in




With LET 2 m 284/412 had a positive and 128/412 a
negative result. The LET 2 m showed a sensitivity of
92.6 % (95 % CI 85.3–97.0), a specificity of 38.1 % (95 %
CI 32.7–43.6 %), a PPV of 30.6 % (95 % CI 27.3–36.4),
an NPV of 94.5 % (95 % CI 89.1–97.8) and a kappa of
0.179 (Table 2). The LET 5 m had a comparable sensitivity
of 96.8 % (p = 0.1936) but a significantly lower specificity
of 16.7 % (p < 0.001). The LET 2 m had a comparable sen-
sitivity among symptomatic and asymptomatic patients,
92.2 % versus 94.1 % (p = 0.786), but the specificity was
significantly lower among the symptomatic patients com-
pared with the asymptomatic patients; 30.2 % versus
51.7 % (p < 0.001).
Among patients <25 years of age the sensitivity was
100 % (95 % CI 90.2–100) for the LET 2 m, although
this was not significantly different compared with the
sensitivity of the those ≥ 25 years; 89.2 % (95 % CI 79.1–
95.6) (p = 0.066). Also the specificity was not significantly
different; 41.3 % (95 % CI 30.9–52.3) versus 37.0 % (95 %
CI 30.8–43.4) (p = 0.496).
The Netherlands
With LET 2 m 301/645 had a positive result and 344/
645 had a negative result. The LET 2 m had a sensitivity
of 77.3 % (95 % CI 67.1–85.5), a specificity of 58.1 % (95
% CI 53.9–62.3), a PPV of 22.6 % (95 % CI 18.0–27.7),
an NPV of 94.2 % (95 % CI 91.1–96.4) and a kappa of
0.176 (Table 3). The sensitivity of the LET 5 m was
90.9 %; significantly higher than the sensitivity of the
LET 2 m (p = 0.013). The specificity of the LET 5 m was
40.8 %; significantly lower than the specificity of the LET
2 m (p < 0.001).
The sensitivity of the LET 2 m was not significantly
different between symptomatic and asymptomatic patients
(p = 0.096), but the specificity was significantly lower
among symptomatic patients (51.0 %) than among asymp-
tomatic patients (62.6 %) (p = 0.008). In the younger age
group (<25 years) a high prevalence of Ct was found
(19.1 %) but the sensitivity and specificity of the LET 2 m
in this group were not significantly different compared
with the age group ≥ 25 years (p = 0.290 and p = 0.377).
Compared with Suriname the sensitivity of the LET 2 m
was significantly lower; 77.3 % versus 92.6 % (p = 0.004).
Discussion
To our knowledge this is the first multi-center study that
evaluated the LET to detect urogenital Ct among men in
clinics in both a middle-income country and in a high-
income country with high Ct prevalences (22.8 % and
13.6 %, respectively).
Both in Suriname and the Netherlands the LET 2 m
had a reasonably high sensitivity (respectively 92.6 and
77.3 %) but a poor specificity (respectively 38.1 and
58.1 %) and a poor agreement (respectively kappa 0.179
and 0.176). The significantly higher sensitivity of the
LET 2 m we found in Suriname compared with the
Netherlands can be caused by a difference in study pop-
ulations. In the Netherlands significantly more patients
were asymptomatic (59.6 %) compared with Suriname
(32.3 %). Wiggins et al. suggested that asymptomatic
patients have infections with a lower infection-load and
therefore fewer leucocytes which might cause false nega-
tive test results [32]. The same group showed that the
number of leucocytes (predominantly PMNL's) was
strongly correlated with urethritis and proved that men
with asymptomatic urethritis have fewer PMNL's than
symptomatic men [33]. A Swedish study conducted among
480 male patients of an STI clinic (also with Ct as
outcome and ≥1+ as cutoff point) supports this hy-
pothesis: the LET had a significantly higher sensitivity
(69.6 % versus 25.9 %) but a lower specificity (76.3 % versus
85.8 %) among symptomatic patients compared with
asymptomatic patients [17].
Moreover, in both countries the LET 2 m showed a
significantly higher specificity in asymptomatic patients
compared with symptomatic patients. A possible explan-
ation can be that symptomatic patients had relatively
more often infections like Neisseria gonorrhoeae (Ng),
Mycoplasma genitalum (Mg) or Trichomonas Vaginalis
(Tv) compared to asymptomatic patients which could
have caused a relative higher proportion of ‘false posi-
tive’ results [34–36]. Also in a previous study we showed
that light microscopic examination of Gram stained
urethral smears is less specific to detect urogenital Ct
infections when done in samples of symptomatic males
only [37].
In the Netherlands the sensitivity of the LET increased
and in both countries the specificity decreased when the
incubation time was prolonged from 2 to 5 min. A study
of Morré et al. found also a higher sensitivity when the
reading time was prolonged from 2 to 5 min [38].
The strength of our study is that we explored the diag-
nostic accuracy of the LET among both symptomatic
and asymptomatic male patients in a high- and in a
middle-income country with a different Ct prevalence. A
shortcoming is that we only focused on Ct and not on
other causative micro-organisms of urethritis like Ng, Mg
or Tv. Evaluation of other micro-organisms could have
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Table 2 Diagnostic performance* of the Leucocyte Esterase Test (LET) after a reading time of 2 min (“LET 2 m”) and 5 min (“LET 5 m”) in the detection of urogenital Chlamydia
Trachomatis (Ct) among male patients, Dermatological Service in Paramaribo, Suriname, 2008–2010
N LET + NAAT+ LET-NAAT+ LET + NAAT- LET- NAAT- Sens. (95 % CI) Spec. (95 % CI) PPV (95 % CI) NPV (95 % CI) Agr. Kappa
LET 2 m
ALL 412 87 7 197 121 92.6 % (85.3–97.0) 38.1 % (32.7–43.6) 30.6 % (27.3–36.4) 94.5 % (89.1–97.8) 50.5 % 0.179
Sympto-matic patients 279 71 6 141 61 92.2 % (83.8–97.1) 30.2 % (24.0–37.0) 33.5 % (27.2–40.3) 91.0 % (81.5–96.6) 47.3 % 0.145
Asympto-matic patients 133 16 1 56 60 94.1 % (71.3–99.9) 51.7 % (42.3–61.1) 22.2 % (13.8–32.9) 98.4 % (91.2–100) 57.1 % 0.193
<25 years 109 29 0 47 33 100 % (88.1–100) 41.3 % (30.4–52.8) 38.2 % (27.2–50.0) 100 % (89.4–100) 56.9 % 0.272
LET 5 m
ALL 412 91 3 265 53 96.8 % (91.0–99.3) 16.7 % (12.7–21.2) 25.6 % (21.1–30.4) 94.6 % (85.1–98.9) 35.0 0.068














Table 3 Diagnostic performance* of the Leucocyte Esterase Test (LET) after a reading time of 2 min (“LET 2 m”) and 5 min (“LET 5 m”) in the detection of urogenital Chlamydia
Trachomatis (Ct) among male patients, STI outpatient clinic, Amsterdam, The Netherlands, 2009–2010
N LET+ NAAT+ LET- NAAT+ LET+ NAAT- LET- NAAT- Sens. (95 % CI) Spec. (95 % CI) PPV (95 % CI) NPV (95 % CI) Agr. Kappa
LET 2 m
ALL 645 68 20 233 324 77.3 % (67.1–85.5) 58.1 % (53.9–62.3) 22.6 % (18.0–27.7) 94.2 % (91.1–96.4) 60.8 % 0.176
Sympto-matic patients 257 44 9 100 104 83.0 % (70.2–91.9) 51.0 % (43.9–58.0) 30.6 % (23.2–38.8) 92.0 % (85.4–96.3) 57.6 % 0.208
Asympto-matic patients 379 23 11 129 216 67.6 % (49.5–82.6) 62.6 % (57.2–67.7) 15.1 % (9.8–21.8) 95.1 % (91.4–97.5) 63.1 % 0.026
<25 years 110 18 3 41 48 85.7 % (63.7–97.0) 53.9 % (43.0–64.6) 30.5 % (19.2–43.9) 94.1 % (84.8–98.8) 60.0 % 0.068
LET 5 m
ALL 645 80 8 330 227 90.9 % (82.9–96.0) 40.8 % (36.7–45.0) 19.6 % (15.9–23.8) 96.6 % (93.4–98.5) 47.6 % 0.125














been helped to interpret the difference of false positive re-
sults between symptomatic and asymptomatic patients.
Another shortcoming is that not all NAAT samples from
Suriname were analyzed within 30 days after collection
(according to manufacturer’s instructions) at the Public
Health Laboratory in Amsterdam; 63 samples (15.3 %)
were analyzed between 31 and 48 days, although it is un-
likely that this small delay has influenced the performance
of the NAAT [39]. Recently, several companies have devel-
oped commercial POC tests that provide rapid results for
the detection of Ct, however, the sensitivity of these tests is
low (25–65 %) and precludes more widespread use in clin-
ical settings [8–10, 40, 41]. An exception of a POC test
with a high sensitivity is the GeneXpert Ct/Ng (Cepheid),
a cartridge-based automated test that can identify Ct and
Ng infections by NAAT within 2 h, but the high costs
hinder the implementation in low-and middle-income
countries [42]. Moreover, not all patients may be willing to
wait for the results for 2 h. Earlier we showed that in the
Surinamese setting only 26.7 % of the female STI visitors
would be willing to wait for their POC test results for
more than one hour [8].
Syndromic management based on symptoms falls short
and leaves many asymptomatic infections untreated
[40, 43]. As long as no accurate and affordable POC tests
for Ct are available, the LET could be a cheap and an easy
to perform alternative to exclude urogenital Ct infections
among men in settings where any Ct diagnostics are lack-
ing. The sensitivity we found for the LET in Suriname
(91.6 %) was reasonably high. It is estimated that a POC
test of even moderate sensitivity (63 %) combined with
immediate treatment on-site may lead to the treatment of
more infected individuals than an ultra-sensitive and
specific NAAT alone when patient return is low [44].
Settings lacking any STI laboratory diagnostics now
mainly rely on syndromic management for STI treat-
ment. Further studies into the diagnostic performance of
the LET test as opposed to routine syndromic manage-
ment are needed; the effect on overtreatment due to low
specificity would be an important end point.
Our previous study on the cost-effectiveness of micro-
scopic examination of Gram stained urethral smears
compared to NAAT at the STI outpatient clinic in
Amsterdam showed a sensitivity of 83.8 % and specificity
of 74.1 %, comparable with the sensitivity and specificity
of the LET we found in the current study [37]. However,
if available, microscopy is preferable above the LET
because it can also detect Ng infections by finding Gram
negative diplococci in a Gram stained smear.
Conclusion
In conclusion, we showed that the LET has a reasonably
high sensitivity but a low specificity to diagnose uro-
genital Ct in male STI clinic visitors. Future studies
that also include the detection of other main causa-
tive infections of urethritis are needed to compare the
cost-effectiveness of the LET in comparison with syn-
dromic management.
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